A not saturated ADA status during infusion is associated with progressive loss of eGFR and ongoing cardiac hypertrophy. Dose escalation can result in saturation of ADAs and decreasing lyso-Gb3 levels, but may lead to increased ADA titers.
No takes yet. Share an insight, caveat, or question.
Lenders et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: